Greater Cannabis Company (GCAN) Net Cash Flow Growth (3y) (2020 - 2026)
Greater Cannabis Company (GCAN) Net Cash Flow Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn | 32.03% |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn | 28.99% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 37.89% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | -49.94% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | 37.74% |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn | -41.05% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | -62.71% |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | 26.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.70% |
| Dec 31, 2025 | -8.19% |
| Sep 30, 2025 | 37.65% |
| Jun 30, 2025 | 29.81% |
| Mar 31, 2025 | -3.95% |
| Dec 31, 2024 | 60.35% |
| Sep 30, 2024 | 37.13% |
| Jun 30, 2024 | -30.67% |
| Mar 31, 2024 | -29.75% |
| Dec 31, 2023 | 20.76% |
| Sep 30, 2023 | 6.17% |
| Jun 30, 2023 | 45.51% |
| Mar 31, 2023 | -27.41% |
| Dec 31, 2022 | 3.46% |
| Sep 30, 2022 | 14.36% |
| Jun 30, 2022 | 12.40% |
| Mar 31, 2022 | -27.95% |
| Dec 31, 2021 | -41.46% |
| Sep 30, 2021 | -28.98% |
| Jun 30, 2021 | 71.17% |